You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-DM1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

Trastuzumab Emtansine as Therapy in Chinese HER2 Positive

Not yet recruiting
  • Breast Cancer
  • Trastuzumab emtansine
  • (no location specified)
Jul 13, 2023

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

Breast Cancer Trial (Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F

Not yet recruiting
  • Breast Cancer
  • Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
  • Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
  • (no location specified)
Feb 22, 2023

Ado-trastuzumab Emtansine-Induced Peripheral Neuropathy in

Recruiting
  • Breast Neoplasm
    • Rochester, Minnesota
      Mayo Clinic Minnesota
    Jun 12, 2023

    Metastatic Solid Tumor, Brain Metastases Trial in Houston (Trastuzumab emtansine, Tucatinib)

    Not yet recruiting
    • Metastatic Solid Tumor
    • Brain Metastases
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 30, 2022

    HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,

    Not yet recruiting
    • HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
    • (no location specified)
    Nov 7, 2023

    Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

    Recruiting
    • Brain Metastases
    • +2 more
    • Saint Louis, Missouri
    • +1 more
    Nov 8, 2022

    Advanced Breast Cancer Trial in Dallas (PD-0332991 and T-DM1)

    Completed
    • Advanced Breast Cancer
    • PD-0332991 and T-DM1
    • Dallas, Texas
      UT Southwestern Medical Center
    Jan 24, 2022

    Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

    Withdrawn
    • Anatomic Stage IV Breast Cancer AJCC v8
    • +3 more
    • Yuma, Arizona
    • +5 more
    May 25, 2022

    HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage Trial in United States (Palbociclib, T-DM1)

    Completed
    • HER2-positive Breast Cancer
    • +5 more
    • Tucson, Arizona
    • +15 more
    Dec 22, 2022

    Breast Cancer Trial in Boston (T-DM1, Pembrolizumab)

    Active, not recruiting
    • Breast Cancer
    • Boston, Massachusetts
    • +1 more
    Jul 25, 2022

    Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

    Completed
    Has Results
    • Breast Cancer
    • Trastuzumab and non-pegylated liposomal doxorubicin
    • Paris, France
    • +3 more
    Feb 8, 2022

    Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant

    Recruiting
    • Breast Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Feb 7, 2022

    HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer Trial in Boston, Nashville (T-DM1, Pertuzumab, Excision of

    Active, not recruiting
    Has Results
    • HER-2 Positive Breast Cancer
    • +3 more
    • T-DM1
    • +2 more
    • Boston, Massachusetts
    • +3 more
    Mar 4, 2022

    Breast Cancer Trial in United States (T-DM1)

    Active, not recruiting
    • Breast Cancer
    • T-DM1
    • Duarte, California
    • +13 more
    Aug 25, 2022

    Breast Cancer, HER2-positive Breast Cancer Trial in United States (trastuzumab-emtansine, Trastuzumab SC, Paclitaxel)

    Recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • Stamford, Connecticut
    • +16 more
    Jun 20, 2022

    HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

    Not yet recruiting
    • HER2 Mutant Non-small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Dec 6, 2022

    Type 1 Diabetes, Type 2 Diabetes Trial in Tunbridge Wells (Four Week Self-Compassion Course)

    Not yet recruiting
    • Type 1 Diabetes
    • Type 2 Diabetes
    • Four Week Self-Compassion Course
    • Tunbridge Wells, United Kingdom
      Salomons Institute for Applied Psychology, Canterbury Christ Chu
    Mar 1, 2023

    HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

    Not yet recruiting
    • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
    • Trastuzumab Emtansine for Injection
    • Pyrotinib Maleate Tablets
    • (no location specified)
    Sep 30, 2022

    Healthy Subjects, Obesity, T2DM (Type 2 Diabetes) Trial in Changchun (HEC88473 injection, Placebo)

    Completed
    • Healthy Subjects
    • +2 more
    • HEC88473 injection
    • Placebo
    • Changchun, Jilin, China
      The First Hospital of Jilin University
    Jul 14, 2023

    NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Maastricht, Limburg, Netherlands
    • +4 more
    Nov 7, 2022

    Trastuzumab Emtansine in HER2-positive Breast Cancer Residual

    Recruiting
    • Breast Cancer
    • Trastuzumab emtansine
    • Prato, Firenze, Italy
    • +27 more
    Mar 2, 2023

    Endothelial Dysfunction, Diabetes, Type 1, Biomarkers Trial in Celje (Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG)

    Completed
    • Endothelial Dysfunction
    • +9 more
    • Semaglutide Pen Injector [Ozempic]
    • Empagliflozin 10 MG
    • Celje, Slovenia
      General Hospital Celje
    May 10, 2023

    Type 2 Diabetes (T2DM) Trial in Montréal (ALN-KHK, Placebo)

    Recruiting
    • Type 2 Diabetes Mellitus (T2DM)
    • MontrĂ©al, Quebec, Canada
      Clinical Trial Site
    Mar 7, 2023